Skip to main content
. 2011 Jul 1;2(7):538–550. doi: 10.18632/oncotarget.302

Table 1.

Effects of Activated Akt-1 Expression on Chemotherapeutic and Hormonal Drugs and Signal Transduction Inhibitors IC50s.1

Cell Line Drug Treatment IC502 or Change in IC503
MCF-7 Doxorubicin 20 nM2
MCF-7/ΔAkt-1(CA) Doxorubicin 2 X↑3
MCF-7/ΔAkt-1(CA)DoxR Doxorubicin 6.7 X↑3
MCF-7 Etoposide 140 nM2
MCF-7/ΔAkt-1(CA) Etoposide 1.5 X↑3
MCF-7/ΔAkt-1(CA)DoxR Etoposide 3.1 X↑3
MCF-7 Paclitaxel 10 nM2
MCF-7/ΔAkt-1(CA) Paclitaxel -3
MCF-7/ΔAkt-1(CA)DoxR Paclitaxel -3
MCF-7 4HT 7 nM2
MCF-7/ΔAkt-1(CA) 4HT 4.3 X↑3
MCF-7/ΔAkt-1(CA)DoxR 4HT 10 X↑3
MCF-7 Rapamycin 7 nM2
MCF-7/ΔAkt-1(CA) Rapamycin 2.5 X↓3
MCF-7/ΔAkt-1(CA)DoxR Rapamycin 7 X↓3

1Determined by MTT analysis as presented in Figures 1 and 2.

2IC50 for MCF-7 cells.

3Comparisons to value obtained in MCF-7 cells. - = baseline with MCF-7 cells or no difference compared to MCF-7 cells. X↑ = fold increase in IC50. X↓ = fold decrease in IC50.